Big pharma missing out on nanotech opportunities, says report
Pharmaceutical companies have been accused of risking missing the opportunities offered by the latest technological zeitgeist, that of nanotechnology
Pharmaceutical companies have been accused of risking missing the opportunities offered by the latest technological zeitgeist, that of nanotechnology.
Consultancy Lux Research has warned that while EU governments are investing in nanotechnology research, large medicine manufacturers are spending very little.
Its report - Why big pharma is missing the nanotech opportunity - claims that this failure could expose the sector to strategic risks, with other industries dominating this emerging technology. Indeed, Lux claims nanotechnology could improve the delivery and effectiveness of medicines, including new treatments such as active implants.
Having spoken to 33 global corporations, the consultants suggest that large pharmaceutical companies commit on average 16 people and less than 0.5% of research spending on nanotechnology. In contrast, large electronics and materials firms commit 100 people and more than 8% of research spending.
